Atlas FDA

ALERE NMP22 BLADDERCHEK TEST

FDA premarket approval P940035/S011 · decided 2015-07-28

Approval details

PMA number
P940035
Supplement
S011
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
ALERE NMP22 BLADDERCHEK TEST
Generic name
System, test, tumor marker, for detection of bladder cancer
Applicant
Abbott Diagnostics Scarborough, Inc.
Date received
2015-07-01
Decision date
2015-07-28
Days to decision
27 days
Decision code
OK30
Product code
NAH
Advisory committee
Immunology
Expedited review
No
Location
Scarborough, ME
Statement
CHANGE IN THE MANUFACTURING PROCESS OF THE ALERE NMP22 BLADDERCHEK TEST, IN WHICH HEAT TREATED NORMAL MOUSE SERUM IS USED INSTEAD OF NORMAL MOUSE SERUM AS A CONTROL TEST LINE BLOCKING AGENT.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
BinaxNOW COVID-19 Ag Card (K250273)Abbott Diagnostics Scarborough, Inc.2025-06-13
BinaxNOW™ COVID-19 Antigen Self Test (K243518)Abbott Diagnostics Scarborough, Inc.2025-02-11
ID NOW Influenza A & B 2 (K232775)Abbott Diagnostics Scarborough, Inc.2023-10-10
ID NOW COVID-19 2.0 (K221925)Abbott Diagnostics Scarborough, Inc.2023-08-10
ID Now Instrument, ID Now Influenza A & B 2, ID NOW Strep A 2 (K220801)Abbott Diagnostics Scarborough, Inc.2022-06-24
ID NOW Influenza A & B 2 (K191534)Abbott Diagnostics Scarborough, Inc.2019-07-11